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Abstract
Programmed remodeling of cell surface glycans by the sequential action of specific
glycosyltransferases, can control biological processes by generating or masking ligands for
endogenous lectins. Galectins, a family of animal lectins with affinity for β-galactosides, can form
multivalent complexes with cell surface glycoconjugates and deliver a variety of intracellular signals
to modulate cell activation, differentiation, and survival. Recent efforts involving genetic or
biochemical manipulation of O- and N-glycosylation pathways, as well as blockade of the synthesis
of endogenous galectins, have illuminated essential roles for galectin-glycoprotein lattices in the
control of biological processes including receptor turnover and endocytosis, host-pathogen
interactions and immune cell activation and homeostasis.
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Introduction
For many systems, the clustering of protein receptors and ligands is required for optimal
transmission of signals into a cell. The thermodynamically favorable assembly of ordered
arrays of lectins and saccharides on the cell surface may thus be integral to cellular signaling
and adhesion [1]. Lectin multivalency enables recognition of multiple binding partners,
allowing these glycan-binding proteins to play leading roles in signal transduction in different
biological processes as well as in cell-cell and cell-pathogen interactions [2–4].
Galectins are a family of soluble lectins that bind β-galactoside-containing glycans and are
defined by a conserved carbohydrate recognition domain (CRD) and a common structural fold
[2–4]. Among the various lectin types, galectins are probably the most conserved and
ubiquitous family, with members identified in most animal taxa examined so far [4]. As many
as fifteen galectins have been identified in mammals and proposed to mediate diverse biological
processes involved in the regulation of innate and adaptive immune responses, such as cell
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activation, differentiation, cytokine secretion and apoptosis [5,6]. Here we discuss recent
findings on the biochemistry of galectin-glycoprotein lattices and their functional relevance in
the control of receptor endocytosis, host-pathogen interactions and activation and homeostasis
of immune cells.
Biochemical aspects of galectin-glycoprotein lattices formation
Lectin-monosaccharide interactions are relatively weak (dissociation constants ~10−4 M), with
two to five hydrogen bonds complemented by hydrophobic and van der Waals interactions
[4,5,7]. Galectins preferentially bind β-galactoside-containing glycans comprised of repeating
units of N-acetyllactosamine (Galβ1,4GlcNAc; LacNAc), either as disaccharide units at the
termini of complex N-glycans, or as repeating units in a poly-N-acetyllactosamine chain on
N- or O-glycans [5,7,8]. Galectin binding affinities to complex N-glycans are proportional to
their LacNAc content and to their GlcNAc branching [5,7–11].
Lattice formation by galectins requires multivalent oligomerization to attain stability and
biologic functionality[5]. Based on structural features, galectins have been classified into three
types: proto, chimera, and tandem-repeat [4]. Proto-type galectins contain one CRD per subunit
and typically dimerize through noncovalent interactions to create functionally bivalent lectins.
Proto-type galectin-1 is a dimer in solution and crystallizes as a dimer in cross-linked
complexes with a divalent oligosaccharide[12]. The presence of more than one CRD in a
galectin-1 homodimer makes it well-suited for mediating cell adhesion, eliciting signaling, and
forming lattices [3,5]. The chimera-type galectin-3 has a C-terminal CRD similar to the proto-
type, but exhibits an N-terminal domain that is responsible for interactions between subunits,
facilitating its oligomerization [3]. Galectin-3 monomers are in equilibrium with higher order
oligomers in solution, and galectin-3 precipitates as a pentamer with multivalent
oligosaccharides [13]. This lectin binds to multi-glycosylated proteins with positive
cooperativity, suggesting that galectin-3 monomers, after ligand binding, recruit additional
lectin molecules to form a complex of multivalent interactions [5,13]. The biologic functions
attributed to galectin-3 are thus likely to depend upon both ligand cross-linking and
oligomerization [6,14–17]. The tandem-repeat type galectins have two CRDs connected by a
linker peptide and, thus are bivalent, although the two CRDs may be able to recognize different
saccharide ligands [6] (Figure 1).
Glycoproteins often bear multiple copies of the saccharide ligands that are recognized by
galectins [18]. While galectin binding to a single saccharide ligand is typically a low-affinity
interaction (association constants ~104 M−1), the multivalent nature of galectin-saccharide
interactions results in high overall avidity (association constants ~106 M−1) [5,9]. This
multivalency also allows the formation of lectin-carbohydrate lattices. Both in solution and on
the cell surface, multivalent galectins selectively cross-link a single species of glycoprotein to
form homogeneous lectin-carbohydrate lattices [5,17,19].
The ability of galectins to reorganize membrane glycoproteins into lipid raft microdomains
suggests that multivalent lectin-saccharide interactions occur preferentially in these
microdomains [5]. In this regard, the ganglioside GM1 is able to organize microdomains into
raft-like structures and is a prominent glycolipid headgroup in such rafts. Galectin-1 binds the
GM1 pentasaccharide glycan and these interactions may represent a mechanism by which
galectins organize lipid rafts [20]. Since lipid rafts are considered essential for assembling
signal transduction components at the plasma membrane [1], association of galectins with lipid
rafts is likely to be important for galectin-mediated signaling events.
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Biological aspects of galectin-glycoprotein lattices
Galectins and receptor turnover
Lattice formation following the binding of complex N-glycans to galectins effectively traps
glycoprotein receptors at the cell surface, preventing their endocytosis. Thus, interactions
between N-glycans and galectins can regulate the distribution of cell surface receptors as well
as the cell’s responsiveness to receptor agonists [11]. Recently, Dennis and colleagues
described a link among N-glycan multiplicity, N-glycan branching kinetics, integration of
nutrient metabolism and changes between cell growth and arrest [10]. The authors described
that N-branching in the Golgi is sensitive to hexosamine flux for its production of complex
N-glycans. Whereas arrest-promoting receptors (e.g., e.g., TGFβR and CTLA-4) have few N-
glycosylation sites and show a ‘switch-like’ responses to hexosamine concentrations, growth-
promoting receptors (e.g., EGFR, IGFR, FGFR, and PDGFR) with high numbers of N-glycans
exhibit hyperbolic responses to hexosamine [10]. Therefore, increased nutrient flux stimulated
by growth-promoting receptors, will ultimately activate cellular arrest and differentiation
programs by increasing surface levels of glycoreceptors with low numbers of N-glycans. The
authors report that increasing UDP-GlcNAc leads to increased branching of N-glycans,
increased receptor association with cell surface galectin-3 and enhanced signaling [10]. Thus,
galectin-carbohydrate lattices can regulate the decision between cell growth and arrest by
regulating receptor turnover (Figure 2).
A second biological example of galectin-mediated control over receptor endocytosis is the
galectin-9-glucose transporter 2 (GLUT-2) system. All vertebrate glucose transporters have a
single conserved N-glycan site. Cell-type and glycoprotein-specific N-glycans attached by N-
acetylglucosaminyltransferase IVa (GlcNAcT-IVa) are needed to maintain the glucose
transporter GLUT-2 on the surface of pancreatic β cells [21]. GlcNAcT-IVa-dependent
glycosylation increases the cell-surface half-life of GLUT-2, suggesting that interactions
involving the GLUT-2 N-glycan structure may suppress its endocytosis. Since GLUT-2 and
galectin-9 normally co-localize in pancreatic β cells in a GlcNAcT-IVa-dependent manner
[21], it is surmised that galectin-9 acts to retain glucose receptors on the cell surface.
Also by interfering with receptor endocytosis, N-acetylglucosaminyltransferase V (GlcNAcT-
V) expression-dependent galectin lattices, such as galectin-3-TGFβR lattices, maintain growth-
factor receptor densities at levels that promote invasive phenotypes in transformed cells [11,
22]. In addition, galectin-3 interactions with GlcNAcT-V-modified N-glycans stimulate α5β1
integrin activation, focal adhesion remodeling and phosphatidylinositol 3-kinase activation,
thus promoting tumor cell motility [23].
Galectin-carbohydrate lattices in host-pathogen interactions
Galectins interact with β-galactoside-enriched glycoconjugates present in several pathogens
[24–26]. While the nature of these interactions is not well-characterized, galectin
oligomerization and/or lattice formation are likely to play a role.
It has been demonstrated that galectin-1 inhibits envelope-mediated cell-cell fusion of some
paramyxoviruses by binding to specific N-glycans on viral glycoproteins and inducing its
oligomerization [27]. However, galectin-1 can also promote human immunodeficiency virus
infectivity by stabilizing viral attachment to host cells and cross-linking viral glycoproteins
with the target cells [28].
Specific interactions have been described between galectin-3 and -9 and the intracellular
protozoan Leishmania. Galectin-3 binds the lipophosphoglycan (LPG) of L. major [26]. This
binding leads to the proteolytic removal of the galectin-3 N-terminal domain, preventing
oligomerization. In this way, L. major destroys galectin-3 lattice formation, leading to a
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decreased threshold for signal transduction [26]. Galectin-9 also recognizes L. major by
binding to LPG and promotes L. major-macrophage interactions, which may be critical for the
clinical outcome of leishmaniasis [25].
Recently, a novel galectin type with four CRDs was discovered in the eastern oyster,
Crassostrea virginica. This molecule binds to endogenous ligands at the surface of the oyster’s
phagocytic cells and recognizes exogenous carbohydrate ligands on microbial pathogens and
phytoplankton components [29]. Although this novel galectin binds β-galactosyl residues, it
exhibits broader saccharide specificity than mammalian galectins, which may confer upon this
oyster galectin biological functions involved in immune recognition, as well as in feeding and
intracellular digestion [29]. Thus galectin-carbohydrate lattices may have evolved to ensure
host-pathogen interactions during the initiation and resolution of microbial infections.
Galectin-glycoprotein lattices in innate immunity
Galectin-carbohydrate lattices may also modulate the biology of innate immune cells at
inflammatory foci [6,15,16]. Galectin-3-mediated ligand clustering triggers neutrophils to
phagocytose, produce reactive oxygen species, release proteases, and secrete interleukin (IL)-8
[15,16,30]. In addition, galectin-3 induces mast cell degranulation: recent studies have revealed
a critical role for this protein in mast cell function since galectin-3-deficient mast cells show
reduced histamine release and IL-4 secretion [14].
Also critical for innate immune responses, macrophages require GlcNAcT-V-dependent
galectin-glycoprotein lattice formation to maintain sufficient cell-surface cytokine receptor
density to drive motility and phagocytosis [11]. Moreover, by interacting with specific
saccharide ligands, galectin-1 differentially regulates Fcγ receptor I-dependent phagocytosis
and inhibits major histocompatibility complex (MHC)-II-dependent antigen presentation by
monocytes/macrophages [31].
Recently, fluorescence resonance energy transfer (FRET) was employed to visualize
physiological galectin-3 oligomerization on the surface of neutrophils and endothelial cells
[15]. Removal of the N-terminal domain of galectin-3 by proteolytic cleavage prevented
oligomerization. These studies further suggested that galectin-3 lattices are robust, stable, and
rigid, with slow lateral movement on the surface of cells, and could thus easily restrict receptor
clustering and modulate cell signaling [15].
Galectin-glycoprotein lattices in T cell functions
Cross-linkage of T-cell surface receptors by galectins can trigger different transmembrane
signaling events through which diverse processes such as survival, activation, and cytokine
secretion are modulated [6].
The T-cell receptor (TCR) α/β is decorated by GlcNAcT-V -modified N-glycans which restrict
nonspecific TCR aggregation through binding to galectins. Multivalent galectin-3-TCR
complex lattices limit TCR clustering at the immune synapse by restricting lateral TCR
movement within the plane of the membrane, thus increasing agonist threshold for TCR
signaling [32,33]. Conversely, deficiency in GlcNAcT-V lowers T-cell activation threshold by
enabling TCR clustering and signaling characterized by increased TCR-dependent tyrosine
phosphorylation and proliferation [32,33].
The authors recently extended their observations, showing that β1,6GlcNAc-branched N-
glycans on T cells are regulated by the nutrient environment and metabolite supply of the
hexosamine pathway. Thus the production of high affinity ligands for galectins is controlled
in T cells by the availability of key metabolic intermediates [34]. Increasing β1,6GlcNAc-
branched N-glycans in T cells by hexosamine supplementation suppresses TCR signaling,
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CTLA-4 endocytosis, Th1 differentiation, and development of autoimmune inflammation
[34] (Figure 2).
A critical process for dampening potential harmful T-cell responses is the fine-tuning of T-cell
survival. Galectin-1, -2, -3 and -9 bind distinct cell surface glycoprotein receptors and trigger
distinct intracellular signaling pathways to promote T-cell death [17,19,35–37]. Remarkably,
a number of factors determine the responsiveness of cells to galectin-mediated signals which
include the repertoire of glycosylated molecules expressed on the cell surface and the activities
of specific glycosyltransferases, which are responsible for creating or masking galectin ligands
[5,6,18]. These variables can dramatically change during thymic-development and peripheral
activation and differentiation of T cells. [5,6,18,38–41].
Compelling evidence indicates that galectin-1 treatment suppresses chronic inflammation,
modulates T-cell survival and skews the balance towards a Th2 cytokine profile in vitro [42]
and in vivo in animal models, including experimental autoimmune uveitis [43] and autoimmune
diabetes [44]. Furthermore, selective blockade of galectin-1 in tumor tissue results in increased
Th1-mediated anti-tumor responses, suggesting potential involvement of this protein in tumor-
immune escape [45]. Recent work provides a molecular explanation for galectin-1-mediated
Th2 skewing, demonstrating that Th1 and Th17 effector cells express the repertoire of cell
surface glycans that are essential for the formation galectin-glycoprotein lattices. In contrast
Th2 cells are protected from galectin-1 binding through differential α2,6-sialylation of cell
surface glycoproteins (Figure 2). Galectin-1-deficient mice consistently developed greater
antigen-specific Th1 and Th17 responses compared to wild-type mice [40]. In addition, other
galectin members may contribute to this immunoregulatory effect, including galectin-9 which
acts as a specific binding partner of Tim-3, a Th1-specific receptor, and selectively eliminates
Th1 cells in vivo [46]. Furthermore, it has been proposed that phosphatidylserine exposure
induced by galectins may serve as an alternative homeostatic mechanism, to favor
phagocytosis, modulate secretion of anti-inflammatory cytokines and influence the resolution
of inflammatory responses [47]. In contrast to the inhibitory actions of galectin-1, galectin-4
contributes to exacerbated intestinal inflammation by promoting CD4+ T cell activation and
favoring IL-6 secretion through a protein kinase Cθ-dependent mechanism [48].
In addition to activation-induced cell death, avoidance of collateral damage to the host is also
achieved by active immunosuppression mediated by regulatory T cells. We found that
treatment with recombinant galectin-1 in the efferent phase of autoimmune ocular
inflammation results in increased IL-10 and TGF-β production and expansion of regulatory T
cells in vivo [43]. Interestingly, recent studies demonstrated that galectin-1 and -10 are over-
expressed in regulatory T cells, and are critical for the suppressive activity of these cells [49,
50]. Further studies are needed to establish a role of galectin-carbohydrate lattices at synapse
formation between regulatory and effector T cells.
Galectin-glycoprotein lattices in B-cell functions
VpreB, a surrogate immunoglobulin light chain that functions in early stages of B-cell receptor
(BCR) maturation in pre-B cells, interacts with galectin-1 to modulate essential B-cell
maturation activities [51]. An immune developmental synapse is formed between pre-B and
stromal cells in a galectin-1-dependent manner: pre-BCR binding to stromal cells depends upon
galectin-1 binding to glycosylated α4β1, α5β1, and α4β7 integrins [51,52]. Pre-B cell integrins
and their stromal cell ligands, together with pre-BCR and galectin-1, form a homogeneous
lattice at the contact area between pre-B and stromal cells [52]. The resulting synapse formation
initiates intracellular tyrosine kinase activity and signal transduction from the pre-BCR [51,
52]. In mature B cells, the B cell-specific transcriptional coactivator OCA-B, important for B
cell activation and germinal center formation, interacts with galectin-1. The authors showed
that galectin-1 negatively regulates B-cell proliferation and tyrosine phosphorylation upon
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BCR stimulation [53]. Finally, anergic B cells show up-regulated expression of galectin-1 and
-3, suggesting a possible role for these lectins in the control of B-cell tolerance [54].
Conclusions
Research over the past few years has illuminated critical functions of galectin-glycoprotein
lattices in receptor turnover and cell signaling, thus dictating the choice among cell
proliferation, differentiation and survival, and serving as “on-an-off switch” that controls the
decision between immune cell responsiveness and tolerance. Given the broad spectrum of
immunoregulatory effects in autoimmune diseases and cancer, galectin-carbohydrate lattices
are postulated as targets of novel anti-inflammatory and anti-cancer therapies. However, before
galectin- or glycan-based therapeutic strategies can be fully realized, a more thorough
understanding of the mechanisms by which galectin-carbohydrate lattices modulate cell
function is required. To what extent is there functional redundancy and specificity of action
within the galectin family? What is the precise explanation of the different functions exerted
by the same galectin in different environmental contexts? What are the levels of galectins
attained in vivo during an inflammatory reaction, infectious process or tumor dissemination?
Increased understanding of the biochemistry and biology of galectin-glycoprotein lattices will
provide insights into how the regulation of galectin expression and activity can be exploited
for therapeutic purposes.
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Carbohydrate recognition domain
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Cytotoxic T-lymphocyte-associated protein-4
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EGFR  
Epidermal Growth Factor Receptor
FGFR  
Fibroblast Growth Factor
FRET  
Fluorescence resonance energy transfer
GLUT-2  
Glucose transporter-2
IGFR  
Insulin-like growth factor receptor
IL  
Interleukin
LacNAc  
N-acetyllactosamine
LPG  
Lipophosphoglycan
GlcNAcT-IVa 
N-acetylglucosaminyltransferase IVa
GlcNAcT-V  
N-acetylglucosaminyltransferase V
MHC  
Major histocompatibility complex
PDGFR  
Platelet-derived growth factor receptor
TCR  
T cell receptor
TGF-β  
Transforming growth factor-β
TGFβR  
Transforming growth factor-β receptor
Th  
T helper
Tim-3  
T cell immunoglobulin mucin-3
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Figure 1. Biochemistry and functional relevance of galectin-glycoprotein lattices
(A) Schematic representation of the structure of different monomeric and oligomeric members
of the galectin family. Proto-type galectins contain one CRD and exist in solution as
homodimers. Chimera-type galectins are thought to undergo a conformational change
following carbohydrate ligand binding which enables their oligomerization as pentamers.
Tandem-repeat type galectins contain two distinct CRDs in tandem, connected by a linker of
up to 70 amino acids, and are thus inherently dimeric. (B) Schematic representation of lattice
formation between multivalent galectins and multivalent carbohydrate ligands. (C) Biological
relevance of galectin-glycoprotein lattices.
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Figure 2. Galectin-glycoprotein lattices in the regulation of receptor turnover, cell signaling and
survival
(A) The degree of N-glycan branching controls galectin-glycoprotein lattice formation, which
in turn modulates receptor turnover and signaling. (B) Differential sialylation of cell surface
glycoproteins selectively influences the formation of galectin-glycoprotein lattices in distinct
T-helper cells, thus regulating their susceptibility to galectin-1-induced cell death.
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